Global biosimulation market to reach $9.18 billion by 2029, driven by drug discovery segment

From GlobeNewswire: 2024-11-22 07:30:00

The global biosimulation market is expected to grow from USD 4.24 billion in 2024 to USD 9.18 billion by 2029, with a CAGR of 16.7%. Biosimulation helps predict drug effects, reducing clinical trial failures. The drug discovery segment is projected to dominate, driven by rising disease burden and technological advancements. Pharmaceutical and biotechnology companies are major end users, relying heavily on biosimulation tools for drug development and clinical trials. Key players include Certara USA, Dassault Systèmes, and Schrödinger, using strategies like collaborations and product launches to enhance their market position.

Certara USA provides Model-informed Drug Development solutions globally, aiding drug development stages. Dassault Systèmes offers 3D design and simulation software for various industries worldwide. Schrödinger specializes in chemical simulation software for drug discovery, serving clients globally. Market leaders emphasize innovation and global expansion to provide biosimulation solutions.

For more information on biosimulation companies and market share, visit the provided links for the latest updates and reports.



Read more at GlobeNewswire: Biosimulation Market to Hit USD 9.18 Billion by 2029 with